These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 11054613

  • 1. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH, Decara JM.
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [Abstract] [Full Text] [Related]

  • 2. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H, Saliba W.
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [Abstract] [Full Text] [Related]

  • 3. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 4. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH, Pollak A, Singh SN, Friedrich T.
    J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
    [Abstract] [Full Text] [Related]

  • 5. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
    Wolbrette DL, Hussain S, Maraj I, Naccarelli GV.
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):3-10. PubMed ID: 29940780
    [Abstract] [Full Text] [Related]

  • 6. Dofetilide: a class III-specific antiarrhythmic agent.
    Kalus JS, Mauro VF.
    Ann Pharmacother; 2000 Jan; 34(1):44-56. PubMed ID: 10669186
    [Abstract] [Full Text] [Related]

  • 7. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R, Sami M.
    Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, Graff O, Simonsen EH.
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [Abstract] [Full Text] [Related]

  • 9. Dofetilide versus quinidine for atrial flutter: viva la difference!?
    Olshansky B.
    J Cardiovasc Electrophysiol; 1996 Sep; 7(9):828-32. PubMed ID: 8884511
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE, Baquero GA, Nickolaus MJ, Wolbrette DL, Kelleman JJ, Samii S, Grando-Ting J, Penny-Peterson E, Davidson WR, Young SK, Naccarelli GV, Gonzalez MD.
    Congenit Heart Dis; 2014 Sep; 9(3):221-7. PubMed ID: 23947935
    [Abstract] [Full Text] [Related]

  • 11. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN.
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [Abstract] [Full Text] [Related]

  • 12. Practical approach to the use and monitoring of dofetilide therapy.
    Tran A, Vichiendilokkul A, Racine E, Milad A.
    Am J Health Syst Pharm; 2001 Nov 01; 58(21):2050-9. PubMed ID: 11715827
    [Abstract] [Full Text] [Related]

  • 13. Dofetilide, a new class III antiarrhythmic agent.
    Lenz TL, Hilleman DE.
    Pharmacotherapy; 2000 Jul 01; 20(7):776-86. PubMed ID: 10907968
    [Abstract] [Full Text] [Related]

  • 14. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
    Cha Y, Wales A, Wolf P, Shahrokni S, Sawhney N, Feld GK.
    J Cardiovasc Electrophysiol; 1996 Sep 01; 7(9):809-27. PubMed ID: 8884510
    [Abstract] [Full Text] [Related]

  • 15. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
    Saliba WI.
    Cleve Clin J Med; 2001 Apr 01; 68(4):353-63. PubMed ID: 11326815
    [Abstract] [Full Text] [Related]

  • 16. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW.
    J Cardiovasc Pharmacol; 1992 Apr 01; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
    Frost L, Mortensen PE, Tingleff J, Platou ES, Christiansen EH, Christiansen N.
    Int J Cardiol; 1997 Jan 31; 58(2):135-40. PubMed ID: 9049678
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
    Suttorp MJ, Polak PE, van 't Hof A, Rasmussen HS, Dunselman PH, Kingma JH.
    Am J Cardiol; 1992 Feb 01; 69(4):417-9. PubMed ID: 1734660
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
    Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB.
    Circulation; 2000 Nov 07; 102(19):2385-90. PubMed ID: 11067793
    [Abstract] [Full Text] [Related]

  • 20. Dofetilide: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
    Shenasa F, Shenasa M.
    Card Electrophysiol Clin; 2016 Jun 07; 8(2):423-36. PubMed ID: 27261832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.